Screening for Type 2 Diabetes in Pediatrics
Screen children aged 10 years or older (or at puberty onset, whichever comes first) who have overweight (BMI ≥85th percentile) or obesity (BMI ≥95th percentile) AND at least one additional risk factor for type 2 diabetes. 1, 2
Who to Screen: Risk Criteria
Begin screening at age 10 years or at puberty onset (whichever is earlier) in children with:
Required Criterion:
- Overweight (BMI ≥85th percentile) OR Obesity (BMI ≥95th percentile)
PLUS One or More of These Risk Factors (in order of strength):
Strongest Risk Factors:
- Maternal history of diabetes or gestational diabetes during the child's gestation 1, 2, 3
- Family history of type 2 diabetes in first- or second-degree relative 1, 2, 3
Additional Risk Factors:
- High-risk race/ethnicity: Native American, African American, Latino/Hispanic, Asian American, Pacific Islander 1, 2, 3
- Signs of insulin resistance: acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome 1, 2, 3
- Small-for-gestational-age birth weight 2, 3
- Use of obesogenic psychotropic medications 2
Recommended Tests
All three tests are acceptable for screening—choose based on patient access, convenience, and clinical setting 1, 2:
- Fasting Plasma Glucose (FPG) - Most practical, requires 8-hour fast
- 2-hour Plasma Glucose during 75-gram Oral Glucose Tolerance Test (OGTT) - More sensitive but time-consuming (2+ hours)
- Hemoglobin A1C (HbA1c) - No fasting required, but can vary by age, ethnicity, and hemoglobinopathies
Diagnostic Cutoffs:
Prediabetes:
Diabetes:
Important Testing Caveats:
- Do NOT use fasting insulin as a screening test—it is not reliable for insulin resistance 2
- If using OGTT, ensure adequate carbohydrate intake (≥150 g/day) for 3 days prior 1
- Test for pancreatic autoantibodies in children with suspected type 2 diabetes to exclude autoimmune type 1 diabetes, especially if obesity is present 2, 4
- Concordance between tests is imperfect—if initial result is equivocal, use OGTT for confirmation 2
Follow-Up Recommendations
If Tests Are Normal:
- Repeat screening every 3 years minimum 1, 3, 5
- Screen more frequently (potentially every 2 years) if: 2, 4
- BMI is increasing
- Risk factor profile is deteriorating
- New symptoms develop
If Prediabetes Is Identified:
- Test yearly 1, 3
- Initiate intensive lifestyle modification (nutrition counseling, physical activity)
- Monitor for progression to diabetes
If Diabetes Is Diagnosed:
- Confirm diagnosis with repeat testing on a different day (unless unequivocal hyperglycemia with symptoms) 2
- Immediate referral to pediatric endocrinology
- Initiate treatment based on presentation severity 6, 4
Critical Clinical Pitfalls to Avoid
The most recent 2024 ADA guidelines 1 and 2023 AAP Obesity Guidelines 2 provide the strongest evidence base. Key points:
- Do not screen the general pediatric population—only screen high-risk children meeting the criteria above. Mass screening is not recommended 5, 7
- Do not delay screening until after age 10 if puberty begins earlier—insulin resistance increases during puberty 2, 8
- Do not assume obesity alone warrants screening—at least one additional risk factor must be present (though clinical judgment can override this) 1, 2
- Do not miss type 1 diabetes—up to 85% of youth with type 2 diabetes have obesity, but autoimmune diabetes can coexist. Test autoantibodies when diagnosis is uncertain 2, 4
- Do not use point-of-care HbA1c for diagnosis—only laboratory methods certified by NGSP and standardized to DCCT assay are acceptable 9
Special Populations:
Research evidence shows that Black youth have higher rates of elevated glucose values (30%) compared to White youth (13%) when screened, and youth with severe obesity have the highest rates (27%) 10. This underscores the importance of targeted screening in high-risk populations rather than universal screening.
The evidence consistently demonstrates that type 2 diabetes in youth progresses more rapidly than in adults, with faster decline in beta-cell function and earlier onset of complications 4, 8. Early identification through appropriate screening is therefore critical for preventing long-term morbidity and mortality.